The efficacy of shortening the dosing interval to once every six weeks in Crohn’s patients losing response to maintenance dose of infliximab-Reference-Cited by-同舟云学术

The efficacy of shortening the dosing interval to once every six weeks in Crohn’s patients losing response to maintenance dose of infliximab

Published:2010-12-01 Issue:3 Volume:33 Page:349-357
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:

Author:

Kopylov U.,Mantzaris G. J.,Katsanos K. H.,Reenaers C.,Ellul P.,Rahier J. F.,Israeli E.,Lakatos P. L.,Fiorino G.,Cesarini M.,Tsianos E. V.,Louis E.,Ben-Horin S.

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2036.2010.04523.x/fullpdf

Reference17 articles.

1. Maintenance infliximab for Crohn’s disease: the ACCENT 1 randomized trial;Hanauer;Lancet,2002

2. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn’s disease;Lichtenstein;Gastroenterology,2005

3. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn’s disease;Hanauer;Clin Gastroenterol Hepatol,2004

4. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease;Rutgeerts;Gastroenterology,2004

5. Long-term outcome of treatment with infliximab in 614 patients with Crohn’s disease: results from a single-centre cohort;Schnitzler;Gut,2009

Cited by 81 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment Targets Should Influence Choice of Infliximab Dose Intensification Strategy in Inflammatory Bowel Disease: A Pharmacokinetic Simulation Study;BioDrugs;2024-08-22

2. Changes in the intensified regimen of infliximab in patients with inflammatory bowel disease in sustained remission: Reflections on a series of cases;Gastroenterología y Hepatología (English Edition);2024-08

3. IBD: From conventional immunosuppression to biological therapy;Digestive Diseases;2023-12-14

4. Cambio de pauta de intensificación de infliximab en pacientes con enfermedad inflamatoria intestinal en remisión mantenida. Reflexiones a propósito de una serie de casos;Gastroenterología y Hepatología;2023-08

5. Dose Escalation Patterns of Advanced Therapies in Crohn’s Disease and Ulcerative Colitis: A Systematic Literature Review;Advances in Therapy;2023-03-17